Vimta Labs has reported its audited financial results for the fourth quarter and full year ended March 31, 2026, with the Board meeting held on May 06, 2026. The company delivered robust growth across key metrics, with standalone net profit (PAT) for Q4 FY26 rising to ₹211.13 million from ₹183.19 million in the year-ago quarter, marking a 15.2% year-on-year increase. Revenue from operations for the quarter stood at ₹1,092.45 million, up significantly from ₹944.41 million in Q4 FY25. Beyond the financial results, the Board approved several strategic and governance actions, including the incorporation of a wholly owned subsidiary in the USA.

Key Financial Highlights

The company's performance showed improvement across all major metrics on both a year-on-year and quarter-on-quarter basis. The following table summarizes the key financial figures:

For the full fiscal year FY26, Total Income reached ₹4,162.79 million, up 19.50% from ₹3,482.22 million in FY25. Net Profit for the year increased to ₹775.12 million from ₹667.55 million in FY25 (from continuing operations). Basic EPS from continuing operations stood at 17.40 INR, while Diluted EPS stood at 17.20 INR for FY26.

Operational Efficiency and Balance Sheet Strength

Vimta Labs posted EBITDA of ₹421 million for Q4 FY26, reflecting strong operational efficiency. The EBITDA margin expanded to 37.60% from 36.10% in the year-ago quarter and 34.30% in Q3 FY26. Total expenses for Q4 FY26 stood at ₹829.49 million, compared to ₹710.54 million in Q4 FY25. The company's balance sheet as of March 31, 2026 reflects a healthy financial position, as detailed below:

Net cash flows generated from operating activities for the year ended March 31, 2026 stood at ₹1,471.42 million, compared to ₹940.54 million in the prior year. Net cash used in investing activities was ₹1,296.68 million, primarily driven by payments for property, plant and equipment and capital work-in-progress of ₹996.80 million. Cash and cash equivalents at the end of the year stood at ₹229.69 million.

Corporate Actions and Strategic Developments

The Board approved several significant actions at its meeting. The following table summarizes the key corporate decisions:

The dividend recommendation and the reappointment of Dr. S. P. Vasireddi as Executive Chairman are subject to shareholder approval at the ensuing Annual General Meeting. Additional information regarding the US subsidiary incorporation, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, will be disclosed in due course.

Bonus Shares and ESOP

Pursuant to shareholder approval at the 35th Annual General Meeting held on June 06, 2025, the company issued bonus shares in the ratio of 1:1, allotting 2,22,52,784 equity shares on June 14, 2025 to shareholders on record as of June 13, 2025. Consequently, ₹44.51 million (representing par value of ₹2 per share) was transferred from Securities Premium to the Share Capital Account. Earnings per share for all prior periods have been proportionately adjusted. Regarding the Employee Stock Option Plan (ESOP), the company applied to the stock exchanges for in-principle approval of 5,18,260 ESOP grants arising from the bonus issue, receiving approvals from BSE on August 29, 2025 and from NSE on September 01, 2025. The company operates in a single reportable segment, namely 'Contract Research and Testing Services', as assessed under Ind AS-108. The audited financial results carry an unmodified opinion from statutory auditors M/s Gattamaneni & Co., Chartered Accountants.

Vimta Labs Limited has informed stock exchanges that its Board of Directors, at their meeting held on May 6, 2026, has recommended the re-appointment of Dr. S. P. Vasireddi (DIN: 00242288) as Executive Chairman of the company. The recommendation was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was based on the recommendations of the Nomination and Remuneration Committee and the approval of the Audit Committee.

Re-appointment Details

The proposed re-appointment is subject to the approval of shareholders at the ensuing Annual General Meeting. The key details of the re-appointment are outlined below:

As Dr. S. P. Vasireddi has attained the age of 77 years, his re-appointment and continuation as Executive Chairman is subject to approval of the members of the company by way of a special resolution at the ensuing Annual General Meeting, as per the provisions of Section 196(3)(a) of the Companies Act, 2013. He is also liable to retire by rotation.

Profile and Experience

Dr. S. P. Vasireddi is the founder of Vimta Labs and has been associated with the company since its inception, playing a pivotal role in its growth and development over the past four decades. His tenure with the company has spanned several key roles:

• Served as Chairman & Managing Director until July 13, 2013
• Served as Executive Chairman up to June 30, 2018
• Served as Non-Executive Chairman from July 1, 2018 to June 30, 2023
• Resumed the position of Executive Chairman following the above tenure

Dr. Vasireddi brings over four decades of industry experience, with expertise in strategic leadership, business development, and corporate governance, contributing to the company's sustained growth and long-term objectives. He has also been instrumental in setting up a centre of excellence — the VIMTA-UNIDO South Cooperation Training Centre.

Advisory and Governing Board Associations

Given his extensive knowledge and experience, Dr. Vasireddi has been nominated as a member on the Advisory/Governing Boards of several apex scientific bodies. His present/past associations include:

• Member of Central Advisory Committee – Food Safety & Standards Authority of India (FSSAI)
• Member of the Governing Board of NABL
• Chairperson – NABL, Risk Management Committee

Additional Disclosures

The following additional disclosures have been made in accordance with regulatory requirements:

The intimation was filed by Sujani Vasireddi, Company Secretary and Compliance Officer of Vimta Labs, in compliance with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.